Literature DB >> 31389906

Antithrombin III Contributes to the Protective Effects of Fresh Frozen Plasma Following Hemorrhagic Shock by Preventing Syndecan-1 Shedding and Endothelial Barrier Disruption.

Ernesto Lopez1,2, Zhanglong Peng1,2, Rosemary A Kozar3, Yanna Cao4, Tien C Ko4, Charles E Wade1,2, Jessica C Cardenas1,2.   

Abstract

BACKGROUND: Endothelial dysfunction during hemorrhagic shock (HS) is associated with loss of cell-associated syndecan-1 (Sdc1) and hyperpermeability. Fresh frozen plasma (FFP) preserves Sdc1 and reduces permeability following HS, although the key mediators remain unknown. Antithrombin III (ATIII) is a plasma protein with potent anti-inflammatory and endothelial protective activity. We hypothesized that the protective effects of FFP on endothelial Sdc1 and permeability are mediated, in part, through ATIII.
METHODS: ATIII and Sdc1 were measured in severely injured patients upon admission (N = 125) and hospital day 3 (N = 90) for correlation analysis. In vitro effects of ATIII on human lung microvascular endothelial cells (HLMVECs) were determined by pretreating cells with vehicle, FFP, ATIII-deficient FFP, or purified ATIII followed by TNFα stimulation. Sdc1 expression was measured by immunostaining and permeability by electrical impedance. To determine the role of ATIII in vivo, male mice were subjected to a fixed pressure exsanguination model of HS, followed by resuscitation with FFP, ATIII-deficient FFP, or ATIII-deficient FFP with ATIII repletion. Lung Sdc1 expression was assessed by immunostaining.
RESULTS: Pearson correlation analysis showed a significant negative correlation between plasma levels of Sdc1 and ATIII (R = -0.62; P < 0.0001) in injured patients on hospital day 3. Also, in vitro, FFP and ATIII prevented TNFα-induced permeability (P < 0.05 vs TNFα) in HLMVECs. ATIII-deficient FFP had no effect; however, ATIII restoration reestablished its protective effects in a dose-dependent manner. Similarly, FFP and ATIII prevented TNFα-induced Sdc1 shedding in HLMVECs; however, ATIII-deficient FFP did not. In mice, Sdc1 expression was increased following FFP resuscitation (1.7 ± 0.5, P < 0.01) vs. HS alone (1.0 ± 0.3); however, no improvement was seen following ATIII-deficient FFP treatment (1.3 ± 0.4, P = 0.3). ATIII restoration improved Sdc1 expression (1.5 ± 0.9, P < 0.05) similar to that of FFP resuscitation.
CONCLUSIONS: ATIII plays a role in FFP-mediated protection of endothelial Sdc1 expression and barrier function, making it a potential therapeutic target to mitigate HS-induced endothelial dysfunction. Further studies are needed to elucidate the mechanisms by which ATIII protects the endothelium.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31389906     DOI: 10.1097/SHK.0000000000001432

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  9 in total

1.  Shock-Induced Endothelial Dysfunction is Present in Patients With Occult Hypoperfusion After Trauma.

Authors:  Heather R Kregel; Gabrielle E Hatton; Kayla D Isbell; Hanne H Henriksen; Jakob Stensballe; Per I Johansson; Lillian S Kao; Charles E Wade
Journal:  Shock       Date:  2022-01-01       Impact factor: 3.533

2.  Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

Authors:  Ernesto Lopez; Satoshi Fukuda; Katalin Modis; Osamu Fujiwara; Baigal Enkhtaivan; Raul Trujillo-Abarca; Koji Ihara; Francisco Lima-Lopez; Dannelys Perez-Bello; Csaba Szabo; Donald S Prough; Perenlei Enkhbaatar
Journal:  Pharmacol Res       Date:  2020-11-04       Impact factor: 7.658

3.  Fibrinogen inhibits microRNA-19b, a novel mechanism for repair of haemorrhagic shock-induced endothelial cell dysfunction.

Authors:  Amanda M Chipman; Feng Wu; Rosemary A Kozar
Journal:  Blood Transfus       Date:  2021-01-27       Impact factor: 3.443

4.  Endothelial Dysfunction is Associated With Increased Incidence, Worsened Severity, and Prolonged Duration of Acute Kidney Injury After Severe Trauma.

Authors:  Gabrielle E Hatton; Kayla D Isbell; Hanne H Henriksen; Jakob Stensballe; Martin Brummerstedt; Pär I Johansson; Lillian S Kao; Charles E Wade
Journal:  Shock       Date:  2021-03-01       Impact factor: 3.533

5.  Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Daniel Jost; Sabine Lemoine; Frédéric Lemoine; Clément Derkenne; Sébastien Beaume; Vincent Lanoë; Olga Maurin; Emilie Louis-Delaurière; Maëlle Delacote; Pascal Dang-Minh; Marilyn Franchin-Frattini; René Bihannic; Dominique Savary; Albrice Levrat; Clémence Baudouin; Julie Trichereau; Marina Salomé; Benoit Frattini; Vivien Hong Tuan Ha; Romain Jouffroy; Edouard Seguineau; Rudy Titreville; Florian Roquet; Olivier Stibbe; Benoit Vivien; Catherine Verret; Michel Bignand; Stéphane Travers; Christophe Martinaud; Michel Arock; Mathieu Raux; Bertrand Prunet; Sylvain Ausset; Anne Sailliol; Jean-Pierre Tourtier
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  Fingolimod does not prevent syndecan-4 shedding from the endothelial glycocalyx in a cultured human umbilical vein endothelial cell model of vascular injury.

Authors:  Elissa M Milford; Lara Meital; Anna Kuballa; Michael C Reade; Fraser D Russell
Journal:  Intensive Care Med Exp       Date:  2022-08-18

Review 7.  Alterations in heparan sulfate proteoglycan synthesis and sulfation and the impact on vascular endothelial function.

Authors:  Danielle Pretorius; Robert P Richter; Tanya Anand; Jessica C Cardenas; Jillian R Richter
Journal:  Matrix Biol Plus       Date:  2022-09-07

8.  Fresh frozen plasma attenuates lung injury in a novel model of prolonged hypotensive resuscitation.

Authors:  Amanda M Chipman; Feng Wu; Shibani Pati; Alexander J Burdette; Jacob J Glaser; Rosemary A Kozar
Journal:  J Trauma Acute Care Surg       Date:  2020-08       Impact factor: 3.697

Review 9.  The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance.

Authors:  Sen Guo; XinYi Wu; Ting Lei; Rui Zhong; YiRan Wang; Liang Zhang; QingYi Zhao; Yan Huang; Yin Shi; Luyi Wu
Journal:  Front Cell Dev Biol       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.